Normal-weight patients with a nuclear InsR−/ER+ tumor had the lowest risk for recurrence compared to all other nuclear InsR/ER combinations [HRadj 0.50, 95% confidence interval (CI): 0.25–0.97], while overweight or obese patients with nuclear InsR−/ER− tumors had the worst prognosis (HRadj 7.75, 95% CI: 2.04–29.48). The gene discussed is ESR1; the disease is neoplasm.